GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

RBD5044

RBD5044

Company
Ribocure Pharmaceuticals AB
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for RBD5044 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06797401

    Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

    Not yet reported Ribocure Pharmaceuticals AB 120 participants Est. completion 2027-09-30 4 sites Stand-alone
    Other conditions: Dyslipidemias
    View official trial listing →
  • Completed NCT NCT05539651

    A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044

    Not yet reported Suzhou Ribo Life Science Co. Ltd. 72 participants Est. completion 2024-10-30 1 site Stand-alone
    Other conditions: Health Volunteer
    View official trial listing →
  • Active, not recruiting NCT NCT07587788

    RBD5044 in Chinese Participants With Hypertriglyceridemia

    Not yet reported Ribotek Biopharmaceuticals (Shandong) Co., Ltd 40 participants Est. completion 2027-03 7 sites Stand-alone
    Other conditions: Hypertriglyceridemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.